{"nctId":"NCT01180036","briefTitle":"MEmbranous Nephropathy Trial Of Rituximab","startDateStruct":{"date":"2011-11"},"conditions":["Idiopathic Membranous Nephropathy"],"count":130,"armGroups":[{"label":"Rituximab Treatment Arm","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Rituximab"]},{"label":"Cyclosporine Treatment Arm","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cyclosporine"]}],"interventions":[{"name":"Rituximab","otherNames":["Rituxan, MabThera"]},{"name":"Cyclosporine","otherNames":["Sandimmune"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Idiopathic MN with diagnostic biopsy\n* Female, must be post-menopausal, surgically sterile or practicing a medically approved method of contraception(no birth-control pill)\n* Must be off prednisone or mycophenolate mofetil for \\>1 month and alkylating agents for \\>6 months.\n* angiotensin-converting-enzyme inhibitor (ACEi) and/or Angiotensin II receptor blockers (ARB), for \\>3 months prior to randomization and adequate blood pressure (target BP \\<130/80 millimeter of mercury (mmHg) in \\>75% of the readings, but subjects with BP \\<140/80 mmHg in \\>75% of the readings will be eligible). Patients with documented evidence of \\>3 months treatment with maximal angiotensin II blockade, on an 3-hydroxy-3-methylglutaryl-CoA lyase (HMG-CoA) reductase inhibitor, and BP control (BP \\<140/80 mmHg in \\>75% of the readings) who remain with proteinuria \\>5g/24h may enter and be randomized to RTX/CSA without the need of the run-in/conservative phase of the study.\n* Proteinuria \\>5g/24h on two 24-hour urine collection collected within 14 days of each other\n* Estimated glomerular filtration rate (GFR) â‰¥40 ml/min/1.73m2 while taking ACEi/ARB therapy OR quantified endogenous creatinine clearance \\>40 ml/min/1.73m2 based on a 24-hour urine collection.\n\nExclusion Criteria\n\n* Presence of active infection or a secondary cause of MN (e.g. hepatitis B, systemic lupus erythematosus (SLE), medications, malignancies). Testing for HIV, Hepatitis B and C should have occurred \\<2 years prior to enrollment into the study.\n* Type 1 or 2 diabetes mellitus: to exclude proteinuria secondary to diabetic nephropathy. Patients who have recent history of steroid induced diabetes but no evidence on renal biopsy performed within 6 months of entry into the study are eligible for enrollment.\n* Pregnancy or breast feeding for safety reasons\n* History of resistance to CSA (or other calcineurin inhibitors, e.g. tacrolimus), RTX or alkylating agents (e.g. Cytoxan). Patients who previously responded to CSA/Calcineurin Inhibitor (CNI), RTX or alkylating agents with either a complete remission (CR) or partial remission (PR) but relapsed off CSA/CNI after 3 months or relapsed off RTX or alkylating agent after 6 months are eligible.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Remission Status","description":"The number of subjects to reach the composite of maintaining complete remission or partial remission at 24 months after randomization will be the primary endpoint.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Remission Status","description":"The number of subjects to reach either complete remission or partial remission at 12 months after randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":65},"commonTop":["General","Infections","Musculoskeletal","Nervous system","Gastrointestinal"]}}}